Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.32 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081962 | 1.00 | DGAT1 (0.35) | DGAT1ACACBBACE1ALDH1A1KDM4E | |
| SCHEMBL1661495 | 0.82 | KDM4E (0.42) | DGAT1BACE1ALDH1A1KDM4EPOLB | |
| SCHEMBL1661089 | 0.81 | DGAT1 (0.35) | DGAT1BACE1ALDH1A1KDM4EGAA | |
| SCHEMBL1629161 | 0.81 | DGAT1 (0.47) | DGAT1BACE1ALDH1A1KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL13729434 | 0.81 | KDM4E (0.41) | DGAT1BACE1ALDH1A1KDM4EPOLB | |
| SCHEMBL16978524 | 0.80 | CFTR (0.40) | BACE1KDM4EGAAOPRK1NPC1 | |
| SCHEMBL15543442 | 0.80 | NPSR1 (0.41) | NPSR1OPRK1HTTTSHR | |
| SCHEMBL31231846 | 0.80 | NPSR1 (0.41) | NPSR1OPRK1HTTTSHR | |
| SCHEMBL1395991 | 0.80 | AGBL2 (0.41) | BACE1KDM4EHCAR2ASPHKDM8 | |
| SCHEMBL22770825 | 0.80 | HTT (0.43) | ALDH1A1KDM4EHSD17B10POLBHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4608507-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | Neurocrine Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
| CN-114245794-B | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117580569-A | Heterocyclic aldehyde capture compounds and uses thereof | 奥尔德拉医疗公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117098765-A | Heterocyclic derivatives as Janus kinase inhibitors | 奇斯药制品公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116981459-A | Heterocyclic derivatives as janus kinase inhibitors | 奇斯药制品公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-115989224-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023278816-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-114245794-A | Compounds for the treatment of huntington's disease | PTC医疗公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | DGAT1 4590/4885ACACB 536/4885BACE1 4518/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | DGAT1 2889/4885ACACB 763/4885BACE1 1068/4885 |
| US-20240383870-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDH1A2, ALDH2, SSB | DGAT1 2341/4885ACACB 120/4885BACE1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.